Clinical Trial Results:
A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia. A collaborative study of the Interfant network.
Summary
|
|
EudraCT number |
2016-004674-17 |
Trial protocol |
NL AT BE DK DE CZ FR IT |
Global end of trial date |
07 Mar 2024
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
23 Mar 2025
|
First version publication date |
23 Mar 2025
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
NL59901.078.17
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
Trialregister: NL5993 (= NTR6359) | ||
Sponsors
|
|||
Sponsor organisation name |
Princess Máxima Center for Pediatric Oncology
|
||
Sponsor organisation address |
Heidelberglaan 25, Utrecht, Netherlands, 3584 CS
|
||
Public contact |
Secretariat TDC, Princess Máxima Center for Pediatric Oncology, 0031 889727272, trialmanagement@prinsesmaximacentrum.nl
|
||
Scientific contact |
I.M. van der Sluis, Princess Máxima Center for Pediatric Oncology, 0031 889727272, trialmanagement@prinsesmaximacentrum.nl
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Interim
|
||
Date of interim/final analysis |
31 Aug 2022
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
31 Aug 2022
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
07 Mar 2024
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess the safety of 1 course of blinatumomab added to the Interfant-06 backbone in infants with newly diagnosed ALL.
|
||
Protection of trial subjects |
The interests of the trial subjects are safeguarded by informing the parents verbally and in writing (informed consent), by the possibility of consulting an independent physician, by the possibility of withdrawing from the study without giving reasons, and by following the NVK "Directive on Resistance" and by the monitors involved, monitoring that the trial is conducted, recorded and reported in accordance with the protocol, ICH-GCP and the applicable regulatory requirement(s).
|
||
Background therapy |
Chemotherapy according to the Interfant-06 protocol (= Induction (IA), IB, MARMA, OCTADAD and Maintenance). | ||
Evidence for comparator |
Clinical studies show that blinatumomab is effective and well tolerated in children and adults with ALL who are already pre-treated with intensive chemotherapy. | ||
Actual start date of recruitment |
31 Jul 2018
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety, Efficacy | ||
Long term follow-up duration |
2 Years | ||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Australia: 8
|
||
Country: Number of subjects enrolled |
Austria: 3
|
||
Country: Number of subjects enrolled |
Netherlands: 9
|
||
Country: Number of subjects enrolled |
Belgium: 1
|
||
Country: Number of subjects enrolled |
Czechia: 2
|
||
Country: Number of subjects enrolled |
Denmark: 3
|
||
Country: Number of subjects enrolled |
France: 1
|
||
Country: Number of subjects enrolled |
Germany: 3
|
||
Worldwide total number of subjects |
30
|
||
EEA total number of subjects |
22
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
30
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||
Recruitment
|
|||||||||
Recruitment details |
Study initiation date/first subject first visit: 31 July 2018 Last Patient in: 05 July 2021 Study completion date/last subject last visit: 07 March 2024 30 subjects enrolled | ||||||||
Pre-assignment
|
|||||||||
Screening details |
Newly diagnosed infants with ALL, who are treated according to the Interfant-06 protocol, stratified into the medium or high risk group, and have M1 or M2 marrow at the end of induction (~day 33 bone marrow). | ||||||||
Period 1
|
|||||||||
Period 1 title |
overall trial (overall period)
|
||||||||
Is this the baseline period? |
Yes | ||||||||
Allocation method |
Not applicable
|
||||||||
Blinding used |
Not blinded | ||||||||
Arms
|
|||||||||
Arm title
|
Blinatumomab | ||||||||
Arm description |
1 course of blinatumomab 15 μg/m2/day as a 4 week continuous infusion | ||||||||
Arm type |
Experimental | ||||||||
Investigational medicinal product name |
Blinatumomab
|
||||||||
Investigational medicinal product code |
AMG103
|
||||||||
Other name |
Blincyto
|
||||||||
Pharmaceutical forms |
Infusion
|
||||||||
Routes of administration |
Infusion
|
||||||||
Dosage and administration details |
1 course of blinatumomab 15 μg/m2/day as a 4 week continuous infusion
|
||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
overall trial
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Blinatumomab
|
||
Reporting group description |
1 course of blinatumomab 15 μg/m2/day as a 4 week continuous infusion | ||
Subject analysis set title |
Primary - Safety of blinatumomab
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Incidence of clinically relevant toxicities defined as any toxicity that is possibly or definitely attributable to blinatumomab AND results in permanent discontinuation of blinatumomab or death.
|
||
Subject analysis set title |
Secondary - Toxicity
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Incidence and severity of serious adverse events till start of protocol IB, independently to relationship with blinatumomab
|
||
Subject analysis set title |
Secondary - Interruptions due to Blinatumomab
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Number of treatment interruptions due to toxicity occurring during blinatumomab
|
||
Subject analysis set title |
Secondary - Patients with full course of Blinatumomab
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Proportion of patients that receive a full course (4 weeks) of blinatumomab
|
||
Subject analysis set title |
Secondary - MRD response TP2, TPBlina1, TPBlina2
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
MRD response at the following time-points: TP2 d33 (end of induction), TPblina1 d15 (after initial 15 days of blinatumomab) and TPblina2 d29 (after the complete course of blinatumomab)
|
||
Subject analysis set title |
Secondary - MRD response TP4
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
MRD response at the following time-point: TP4 (end of Protocol IB)
|
||
Subject analysis set title |
Secondary - MRD response in MR patients before OCTADAD
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Proportion of MR patients with MRD >= 5x10-4 before OCTADAD (indication for SCT)
|
||
Subject analysis set title |
Secondary - cCR/CR and post-induction EFS/long term EFS/OS
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
cCR/CR and 6 months post-induction EFS and the long-term EFS and OS
|
||
Subject analysis set title |
Secondary - MRD response at TP2
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
MRD response at the following time-point: TP2 d33 (end of induction)
|
||
Subject analysis set title |
Secondary - MRD response at TP4
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
MRD response at the following time-point: TP4 (end of Protocol IB)
|
||
Subject analysis set title |
Secondary - MRD response TPBlina1
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
MRD response at the following time-point: TPblina1 d15 (after initial 15 days of blinatumomab)
|
||
Subject analysis set title |
Secondary - MRD response TPBlina2
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
MRD response at the following time-point: TPblina2 d29 (after the complete course of blinatumomab)
|
|
|||||||||||
End point title |
Safety [1] | ||||||||||
End point description |
Incidence of clinically relevant toxicities defined as any toxicity that is possibly or definitely attributable to blinatumomab AND results in permanent discontinuation of blinatumomab OR death.
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
From start of blinatumomab till start of chemotherapy according to protocol IB.
|
||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The incidence of clinically relevant toxicities defined as any toxicity that is possibly or definitely attributable to blinatumomab AND results in permanent discontinuation of blinatumomab OR death will be described as percentage of patients and also estimated with the exposure-adjusted incidence rate, calculated as the ratio between the number of these adverse events and the total time at risk form study entry, in weeks. In addition, incidence of death will be calculated. |
|||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Toxicity - SAEs | ||||||||||||
End point description |
Incidence and severity of serious adverse events till start of protocol IB, independently to relationship with blinatumomab
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From start of blinatumomab until start of protocol IB
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
MRD response - TP2, TPBlina1 and TPBlina2 | ||||||||||||||||||||||||
End point description |
MRD response at the following time-points: TP2 d33 (end of induction), TPblina1 d15 (after initial 15 days of blinatumomab) and TPblina2 d29 (after the complete course of blinatumomab)
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
From start to end of Blinatumomab course
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Toxicity - treatment interruptions | ||||||||
End point description |
Number of treatment interruptions due to toxicity occurring during blinatumomab
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Blinatumomab course
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Toxicity - Patients who received full course of Blinatumomab | ||||||||
End point description |
Proportion of patients that receive a full course (4 weeks) of blinatumomab
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
During Blinatumomab course
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
MRD response - TP2 and TP4 | ||||||||||||||||||
End point description |
MRD response at the following time-points: TP2 d33 (end of induction) and TP4 (end of Protocol IB)
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
From Blinatumomab until the end of Protocol Ib
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
MRD Response before OCTADAD/HSCT | ||||||||
End point description |
Proportion of MR patients with MRD ≥ 5x10^-4 before OCTADAD (indication for SCT)
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Before the start of OCTADAD
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
cCR/CR and 6 months post-induction EFS and long term EFS and OS | ||||||||||||||
End point description |
cCR/CR and 6 months post-induction EFS and the long-term EFS and OS
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
From enrollment until 31 August 2022
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From start of blinatumomab till start of chemotherapy according to protocol IB.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
As for the Interfant-06 study, AEs occurring in each treatment phase are reported with the Toxicity Form.
During blinatumomab until start protocol IB all AEs grades are reported with the exception of non-reportable AEs.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
CTCAE | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
4.03
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
(S)AEs from start of blinatumomab until start of protocol IB
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients who had the same adverse event multiple times were counted once, and the highest grade is reported. If a patient had episodes in different adverse event categories, it is counted in each category. CTCAE denotes Common Terminology Criteria for Adverse Events. Only AEs with CTCAE grade >= 3 are mentioned here. Fever of grade 1 occurred twice in one patient. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
15 Nov 2019 |
Protocol amendment no. 1: Editorial changes and changes for clarification; Corrections and changes in contact details; Change in Principal investigator(s) DCOG (NL) and Sponsor representative; Additional information about blinatumomab approvals for new indication; Change of estimated study duration and timelines; Correction of exclusion criteria before start (-d3) of blinatumomab; Correction MRD measurement. |
||
09 Apr 2021 |
Amendment no. 2: Investigator's Brochure with relevant RSI update |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/37099340 |